Etopophos etoposide 1 g (as phosphate) and Etopophos etoposide phosphate 113.6 mg (equivalent to 100 mg etoposide) powder for injection vials and Vepesid etoposide 50 mg capsule blister packs are in short supply, the TGA has advised.
The affected products are:
| ARTG No | ARTG Label | Sponsor | Status |
|---|---|---|---|
| 57483 | Etopophos etoposide phosphate 113.6 mg (equivalent to 100 mg etoposide) powder for injection vial | Bristol-Myers Squibb Australia | Unavailable until 1 April 2017 |
| 77220 | Etopophos etoposide 1 g (as phosphate) powder for injection vial | Bristol-Myers Squibb Australia | Unavailable until 1 April 2017 |
| 10233 | Vepesid etoposide 50 mg capsule blister pack | Bristol-Myers Squibb Australia | Out of stock from 28 February 2017 until 1 April 2017 |
| 10234 | Vepesid etoposide 100 mg capsule blister pack | Bristol-Myers Squibb Australia | Available |
A previous shortage of Vepesid etoposide 100 mg capsule blister pack has been resolved.
Clinicians are asked to take the shortages into account when planning treatment with Etopophos injection vials or Vepesid capsules. For more information the TGA advises health professionals to contact the drug sponsor.